Hca Healthcare, INC 8-K filings

HCA Healthcare, Inc. announced an increase in its subsidiary's commercial paper program from $4 billion to $8 billion.

HCA Healthcare announced its second quarter 2026 financial and operating results, reporting increased revenues and net income, alongside a quarterly cash dividend declaration.

HCA Healthcare announced preliminary Q2 2026 results, anticipating revenue of $20.230 billion and net income of $1.699 billion, while revising its full-year 2026 guidance.

HCA Healthcare announced that Dr. Michael Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026, moving to a transitional role until February 2027.

HCA Healthcare's Annual Meeting saw the election of nine directors, ratification of Ernst & Young LLP as auditors, and approval of executive compensation, while two shareholder proposals were not approved.

HCA Healthcare plans a new senior notes offering to fund the redemption of $2.5 billion in existing debt due in 2026.

HCA Healthcare announced first quarter 2026 financial and operating results, reporting increased revenues and net income, alongside a quarterly cash dividend declaration.

HCA Healthcare, Inc. announced a new performance-based compensation program for executive officers and the upcoming retirement of a long-serving board member.

HCA Healthcare reported robust fourth-quarter and full-year 2025 results, alongside a new $10 billion share repurchase program and an increased quarterly dividend.

HCA Inc., a subsidiary of HCA Healthcare, Inc., completed a public offering of $3.25 billion in senior unsecured notes with maturities ranging from 2030 to 2055, primarily to redeem existing debt and for general corporate purposes.

HCA Healthcare's subsidiary, HCA Inc., announced a proposed public offering of senior notes to fund general corporate purposes and redeem $1.5 billion of 2026 debt.

HCA Healthcare reported robust third-quarter 2025 financial and operating results, leading to an upward revision of its full-year 2025 guidance.

HCA Healthcare announced robust second quarter 2025 financial and operating results, exceeding expectations and leading to an upward revision of its full-year 2025 guidance.

HCA Healthcare, Inc. announced the appointment of John W. Chidsey, III, former Global CEO of Subway, as an independent director to its Board, effective July 15, 2025, expanding the board to ten members.

HCA Inc., a wholly owned subsidiary of HCA Healthcare, Inc., has established a new commercial paper program allowing for the issuance of up to $4.0 billion in unsecured notes to fund general corporate operations.

HCA Healthcare's Board of Directors approved a new compensation program for non-management directors and an amendment to the 2020 Stock Incentive Plan, both effective immediately and subject to stockholder approval where applicable.

HCA Healthcare announces positive Q1 2025 financial results, including revenue growth and increased earnings per share, while reaffirming its 2025 guidance.

HCA Healthcare's Compensation Committee adopted the 2025 Executive Officer Performance Excellence Program, linking executive compensation to EBITDA and quality metrics.

HCA Inc., a subsidiary of HCA Healthcare, Inc., successfully priced a public offering of $5.25 billion in aggregate principal amount of senior notes across various tranches.

HCA Healthcare's subsidiary, HCA Inc., entered into a new $8 billion senior unsecured revolving credit agreement, replacing its existing senior secured credit facilities.

HCA Inc., a wholly-owned subsidiary of HCA Healthcare, plans to offer senior notes to the public, with the proceeds potentially used for general corporate purposes, including repaying existing or future credit facilities.

HCA Healthcare announced its fourth quarter and full year 2024 financial results, highlighted by revenue growth and a new $10 billion share repurchase program.

HCA Healthcare announced positive third-quarter 2024 results, with revenue reaching $17.487 billion and net income of $1.270 billion, while also reaffirming its 2024 guidance despite the impact of recent hurricanes.

HCA Inc., a subsidiary of HCA Healthcare, completed a public offering of $3 billion in senior notes across three tranches with varying maturities.

HCA Healthcare, Inc. and its subsidiary, HCA Inc., have entered into an underwriting agreement for the issuance and sale of $3 billion in senior notes across three tranches.

HCA Healthcare reported strong second-quarter results, exceeding expectations and leading to an increase in their full-year 2024 guidance.

HCA Healthcare reports the retirement of its CFO, appointment of a new principal accounting officer, and the results of its annual stockholder meeting, including the election of directors and voting on various proposals.

HCA Healthcare announced robust first quarter 2024 results, with significant increases in revenue, net income, and adjusted EBITDA, driven by broad-based volume growth.

HCA Healthcare has amended its previous 8-K filing to detail the compensation package for incoming CFO Michael A. Marks, including performance-based incentives tied to EBITDA and quality metrics.

HCA Healthcare has established a new performance-based incentive program for its executive officers and appointed a new Executive Vice President, Chief Legal and Administrative Officer.